Ver­tex, Mod­er­na pre­pare to take their in­haled mR­NA cys­tic fi­bro­sis drug in­to the clin­ic

Ver­tex and Mod­er­na’s part­ner­ship on cys­tic fi­bro­sis is fi­nal­ly start­ing to bear fruit.

The two an­nounced Mon­day morn­ing that the first pro­gram from their col­lab­o­ra­tion will en­ter the clin­ic “in the com­ing weeks” af­ter the FDA cleared its IND. Re­searchers will test the drug, known as VX-522, in adults with cys­tic fi­bro­sis in a sin­gle dose es­ca­la­tion study. Par­tic­i­pants must al­so have “a CFTR geno­type not [be] re­spon­sive to CFTR mod­u­la­tor ther­a­py,” Ver­tex added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER